



HHS Public Access

Author manuscript

Mol Microbiol. Author manuscript; available in PMC 2020 June 01.

Published in final edited form as:

Mol Microbiol. 2019 June ; 111(6): 1449–1462. doi:10.1111/mmi.14229.

Structural basis of transcriptional regulation by the HigA antitoxin

Marc A. Schureck^{#a,2}, Jeffrey Meisner^{#a}, Eric D. Hoffer^a, Dongxue Wang^b, Nina Onuoha^a, Shein Ei Cho^a, Pete Lollar III^c, and Dr. Christine M. Dunham^{a,2}

^aDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, 30322.

^bPresent address: The Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.

^cDepartment of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta; Emory University School of Medicine, Atlanta, GA, 30322.

These authors contributed equally to this work.

Abstract

Bacterial toxin-antitoxin systems are important factors implicated in growth inhibition and plasmid maintenance. Type II toxin-antitoxin pairs are regulated at the transcriptional level by the antitoxin itself. Here, we examined how the HigA antitoxin regulates the expression of the *Proteus vulgaris* *higBA* toxin-antitoxin operon from the Rts1 plasmid. The HigBA complex adopts a unique architecture suggesting differences in its regulation as compared to classical type II toxin-antitoxin systems. We find that the C-terminus of the HigA antitoxin is required for dimerization and transcriptional repression. Further, the HigA structure reveals that the C terminus is ordered and does not transition between disorder-order states upon toxin binding. HigA residue Arg40 recognizes a TpG dinucleotide in *higO2*, an evolutionary conserved mode of recognition among prokaryotic and eukaryotic transcriptional factors. Comparison of the HigBA and HigA-*higO2* structures reveals the distance between helix-turn-helix motifs of each HigA monomer increases by ~4 Å in order to bind to *higO2*. Consistent with these data, HigBA binding to each operator is two-fold less tight than HigA alone. Together, these data show the HigB toxin does not act as a co-repressor suggesting potential novel regulation in this toxin-antitoxin system.


Graphical Abstract

²To whom correspondence should be addressed. christine.m.dunham@emory.edu.

AUTHOR CONTRIBUTIONS

MAS and JM, conception and design, acquisition of data, analysis and interpretation of data, drafting and revising the article. EH, analysis and interpretation of data, revising the article. PL, acquisition of data, analysis and interpretation of data, and revising the article. CMD, conception and design, interpretation of data, drafting and revising the article. DW, NI and SC, acquisition of data.

Data deposition: Crystallography, atomic coordinates, and structure factors have been deposited in the Protein Data Bank, www.pdb.org (PDB codes 6CF1, 6CHV)



Keywords

toxin-antitoxin complex; transcriptional repressor; DNA-binding protein; plasmid maintenance; X-ray crystallography

INTRODUCTION

Nearly all bacteria encode a diverse set of toxin-antitoxin gene pairs with the capacity to limit cell growth in response to environmental stress (Moyed and Bertrand 1983; Gerdes et al. 2005; Gonzalez Barrios et al. 2006; Harrison et al. 2009; Wang et al. 2011). These systems consist of a toxin that inhibits cell growth by blocking essential cellular processes during stress and an antitoxin that neutralizes the toxin during normal growth. Under conditions of stress, the labile antitoxins are proteolytically degraded and the more stable toxins are liberated to inhibit growth (Van Melderen et al. 1994; Christensen et al. 2004). In order for toxin-antitoxins to function as effective governors of cell growth in response to stress, several system parameters must be regulated. Prior to the appearance of stress, a sufficient amount of antitoxin needs to be expressed to maintain toxin quiescence, allowing for normal growth. When stress is encountered, toxins need to be freed from their cognate antitoxins to enable cells to halt their growth (through toxin activity). Since toxins are activated by antitoxin proteolysis, too much antitoxin may dampen the responsiveness of the system and delay growth inhibition. Moreover, too much toxin (an amount that exceeds the capacity of antitoxin neutralization) also needs to be avoided, as this would slow or halt growth in the absence of stress. Therefore, the expression of toxin and antitoxins must be finely regulated for a response to stress.

To establish and maintain the optimal levels of their two system components, bacterial antitoxins typically serve as transcriptional autorepressors that constitute a negative feedback loop (Page and Peti 2016). When the appropriate amount of antitoxin is reached, the antitoxin binds upstream of the toxin-antitoxin operon and represses new transcription. Antitoxins can weakly repress transcription in the absence of their toxin partners ensuring continued transcription until the appropriate amount of toxin is reached (Afif et al. 2001; Overgaard et al. 2008; Garcia-Pino et al. 2010). Often the toxin can serve as a transcriptional co- and anti-repressor depending on its abundance relative to the antitoxin (Afif et al. 2001;

Overgaard et al. 2008; Garcia-Pino et al. 2010). Once a particular ratio of the toxin and antitoxin is exceeded, the toxin functions as an anti-repressor that severely decreases the antitoxin affinity for DNA allowing for transcription. For each toxin-antitoxin transcript, a disproportionate amount of antitoxin is translated because of the presence of a stronger ribosome binding site than the toxin's (Li et al. 2014). In some well-studied toxin-antitoxin systems, toxins exert their co-repressor functions by influencing the structure of their antitoxins. Toxin binding can order intrinsically disordered regions of their antitoxins (Kamada et al. 2003; Garcia-Pino et al. 2010) and can promote and/or disrupt the formation of antitoxin complexes that are proficient for DNA binding (Afif et al. 2001; Kedzierska et al. 2007; Garcia-Pino et al. 2008; De Jonge et al. 2009; Garcia-Pino et al. 2010). Whether these regulatory mechanisms can be generally applied to understand other toxins-antitoxin systems is unknown.

Antitoxin proteins have two major functions during normal growth. They inhibit toxin function by direct binding and repress transcription to limit expression (Loris and Garcia-Pino 2014; Page and Peti 2016). Antitoxins are structurally diverse and contain either a ribbon-helix-helix (RHH) (De Jonge et al. 2009; Boggild et al. 2012), Phd/YefM (Garcia-Pino et al. 2010), SpoVT/AbrB (Dienemann et al. 2011), or a helix-turn-helix (HTH) DNA-binding motifs (Brown et al. 2009; Schumacher et al. 2009; Schureck et al. 2014). These distinct antitoxin architectures raise the possibility that the regulatory mechanisms that establish and maintain the appropriate amounts of antitoxin proteins may be distinct from those that have been established for more traditional systems including CcdAB, RelBE, and bacteriophage P1 Phd-Doc (Afif et al. 2001; Overgaard et al. 2008; Garcia-Pino et al. 2010).

The *host inhibition of growth* BA (*higBA*) operon was identified on the Rts1 plasmid associated with *Proteus vulgaris* in a post-operative urinary tract infection that displayed resistance to antibiotics (Tian et al. 1996). *higBA* is classified as a bacterial toxin-antitoxin pair whereby the HigB toxin protein inhibits protein synthesis by cleaving adenosine-rich mRNA transcripts on actively translating ribosomes (Hurley and Woychik 2009; Schureck et al. 2015; Schureck et al. 2016a; Schureck et al. 2016b). Homologues of HigBA are also chromosomally distributed although their structure and regulation suggest their mechanism may be distinct from *P. vulgaris* HigBA (Christensen-Dalsgaard et al. 2010; Kirkpatrick et al. 2016; Hadzi et al. 2017). Structures of the heterotetrameric *P. vulgaris* HigBA complex (two HigAs and two HigBs) reveal that the HigB toxin is a member of the RelE family of bacterial toxins while the HigA antitoxin contains a HTH DNA-binding motif that recognizes its operator for transcriptional autorepression (Schureck et al. 2014). The structure also indicated a number of differences between the HigBA complex and other RelE toxin-antitoxin family members. For example, other antitoxins that recognize RelE toxin family members typically contain ribbon-helix-helix (RHH) DNA-binding motifs that require dimerization to form a single DNA-binding motif (Kamada and Hanaoka 2005; Boggild et al. 2012; Ruangprasert et al. 2014). HigA antitoxin contains a HTH motif that is a complete DNA-binding motif; therefore, the two HigA antitoxins in the HigBA complex contain two DNA-binding motifs in contrast to other RelE family members that contain a single DNA-binding motif. Another distinction of the *P. vulgaris* HigBA complex is that the HigA antitoxin does not wrap around the HigB toxin for inactivation but, instead, has a C-terminal extension that engages the adjacent HigA. We previously determined that this C-

terminus is critical for HigA dimerization and the HigA dimer is required for binding to its operator (Schureck et al. 2014). In this study, we sought to understand the molecular basis of HigA interaction with its DNA operator.

RESULTS

Dimerization is critical for HigA to repress transcription of *hig*.

The *P. vulgaris* Rts1 plasmid encodes the toxin *higB* gene followed by the antitoxin *higA* antitoxin gene, an inverted gene organization compared as to other RelE family members (Fig. 1A) (Gerdes et al. 2005). The *hig* promoter (*Phig*) controls the transcription of both genes and is regulated by two operator sites (*higO1* and *higO2*) that overlap with portions of the *Phig* -35 and -10 promoter sites. The HigA protein binds both operators and represses transcription from *Phig*. We previously purified a HigA lacking its C-terminal 21 amino acids (84–104) that disrupts HigA dimerization in the context of the HigBA complex (Schureck et al. 2014). Although each monomeric HigA variant contained a complete HTH DNA-binding motif, the HigA monomer was unable to bind to its DNA operator as assessed by EMSA. Additionally, disruption of the HigA dimer had no impact on the ability of a monomer of HigB to bind *in vitro*. We next wanted to test that the HigA C-terminal truncation specifically disrupted the transcriptional repression function of HigA *in vivo* while preserving its toxin neutralization function. The toxin *higB* gene, without or with either the full-length or truncated antitoxin *higA* gene, was placed under the control of the arabinose-inducible expression pBAD promoter. The expression plasmids were introduced into *E. coli* BW25113 and grown to mid-exponential growth phase in rich medium, serially diluted, and spotted onto agar plates without or with 0.2% arabinose (to induce gene expression). Cell growth was inhibited when expression of the *higB* toxin gene was induced in the absence of *higA* and normal cell growth was restored when HigB and full-length HigA were co-expressed, as previously observed (Tian et al. 1996) (Fig. 1B). Importantly, normal cell growth was also observed when HigB and the truncated HigA were co-expressed, indicating that the C-terminal portion of HigA is dispensable for its toxin neutralization function *in vivo* (Fig. 1B). Thus, dimerization appears to be feature of HigA that is dedicated to its transcriptional repression function rather than toxin neutralization.

To better understand how HigA controls *higBA* gene expression *in vivo*, we constructed a series of transcriptional reporters for the *hig* promoter. First, the *hig* promoter was cloned upstream of the *lacZ* gene (encoding the β -galactosidase enzyme) in the transcriptional reporter plasmid pQF50. Next, either the full-length or truncated *higA* gene (84–104) was cloned between the *hig* promoter and the *lacZ* reporter gene, creating two different synthetic bicistronic operons where both *higA* and *lacZ* are expressed under the control of the *hig* promoter. The transcriptional reporter plasmids were introduced into *E. coli* BW25113 and grown to mid-exponential phase in rich medium and β -gal activity was measured (Fig. 1C). The strain containing the transcriptional reporter without *higA* (*Phig-lacZ*) produced ~600 Miller units (MU) of β -gal activity (Fig. 1C). In the strain containing the transcriptional reporter with the full-length *higA* (*Phig-higA-lacZ*), this activity was decreased nearly 60-fold (from ~630 to ~10 MU) through the transcriptional repression function of HigA. The strain bearing the transcriptional reporter with *higA*(84–104) that disrupts HigA

dimerization (*Phig-higA 84–104-lacZ*), however, had nearly the same amount of β -gal activity as the reporter without *higA* (~590 MU) (Fig. 1C). One possible interpretation could be that HigA(84–104) expression is compromised. However, since coexpression of this variant with HigB leads to normal growth (Fig. 1B), this strongly suggests that HigA(84–104) expression is sufficient to suppress HigB toxicity. Collectively, these data demonstrate that dimerization of HigA is necessary for transcriptional repression.

In the pQF50-*Phig-higA-lacZ* transcriptional reporter plasmid, the level of *higA* gene expression is a product of the strength of the *hig* promoter and HigA-mediated transcriptional repression. The configuration of this reporter system is simple and convenient but it lacks the ability to compare the transcriptional repression of HigA variants at defined expression levels. To perform this analysis, either the full-length or truncated *higA* gene (84–104) was cloned into the arabinose-inducible expression plasmid pBAD33. The expression plasmids were then introduced into *E. coli* BW25113 bearing the *Phig-lacZ* transcriptional reporter (without *higA*). The strains were grown to mid-exponential phase in minimal medium (M9 maltose) supplemented with 0.2% arabinose and β -gal activity was measured. The strain with the *Phig-lacZ* transcriptional reporter and pBAD33 (without *higA*) produced ~4200 MU of β -gal activity (Fig. 1D). The β -gal activity in the strain containing pBAD33 with the full-length *higA* was decreased more than 20-fold (~150 MU), demonstrating that the amount of HigA produced at this expression level could effectively repress transcription from the *hig* promoter in trans (Fig. 1D). The strain containing pBAD33 with the truncated HigA(84–104) was incapable of high levels of transcriptional repression as assessed by its high level of β -gal activity (~3000 MU). These results show that, at defined HigA expression levels, dimerization is necessary for HigA to repress transcription activity from the *hig* promoter. Additionally, the results show that HigA is capable of repressing transcription from the *hig* promoter in the absence of HigB, suggesting that HigB co-repressor function may not be necessary in the HigBA system. This seems to be in contrast to the prevailing models used to describe the transcriptional control of other toxin-antitoxin systems where the toxin is often necessary for effective transcriptional repression by the antitoxin (Afif et al. 2001; Overgaard et al. 2008; Garcia-Pino et al. 2010). This is not a trivial distinction between these systems, as conditional toxin co- and anti-repressor function is the central tenant used to understand how toxin-antitoxin systems control the expression of their own genes to be primed to respond to stress. These data strongly suggest that the molecular mechanisms that underpin the priming of HigBA are distinct from those that explain systems including RelBE, Phd-Doc, CcdAB, MqsRA, DinJ-YafQ and HicAB (Afif et al. 2001; Overgaard et al. 2008; Garcia-Pino et al. 2010; Brown et al. 2013; Ruangprasert et al. 2014; Turnbull and Gerdes 2017).

Distance between HigA HTH motifs increases in the absence of HigB.

The X-ray crystal structure of the heterotetrameric HigBA complex revealed how the antitoxin HigA inhibits HigB but whether the toxin HigB influences the overall conformation of HigA was unclear (Schureck et al. 2014). This is important because in other toxin-antitoxin systems, the toxin can profoundly influence the ordering of antitoxin regions that are intrinsically disordered (Kamada and Hanaoka 2005; Li et al. 2008; De Jonge et al. 2009; Garcia-Pino et al. 2010). This disordered-to-ordered transition has been shown to be

important for stabilization of the antitoxin for transcriptional repression (Loris and Garcia-Pino 2014). In the heterotetrameric HigBA complex, the last eleven C-terminal residues of HigA (amino acids 94–104) are disordered in the presence of HigB but this region does not interact with HigB (Schureck et al. 2014). We next solved the X-ray crystal structure of antitoxin HigA in the absence of HigB to 1.9 Å (Fig. 2A; Table S1). HigA crystallizes in the C2 space group with one HigA dimer per asymmetric unit. The final HigA model was built for residues 3–94 and 6–99 (out of 104 total residues) for monomers A and B of the dimer, respectively. HigA is a single domain protein and adopts a compact, five α -helix bundle with $\alpha 2$ and $\alpha 3$ comprising the HTH motif that is exposed at its N-terminus (Fig. 2A). HigA dimerization is mediated via interactions between $\alpha 5$ and its C-termini that extend to interact with each HigA monomer. Recognition of the *hig* operator is likely mediated by $\alpha 3$ while $\alpha 2$ helps to position $\alpha 3$ in the major groove consistent with other classical bacteriophage transcriptional repressors that HigA structurally resembles (Shimon and Harrison 1993; Watkins et al. 2008). These bacteriophage repressors form dimers that separate the recognition helices, one from each monomer, by the same distance as successive major grooves of the operator DNA. Sedimentation velocity analytical ultracentrifugation (AUC) studies show that HigA is a 2.15 *S* particle with an estimated molecular mass of 25.9 kDa (the molecular mass of each HigA polypeptide is 11.5 kDa) providing additional support that HigA is a dimer (Fig. 2B).

The overall structural architecture of the HigA dimer remains largely unchanged in the presence or absence of the toxin HigB (root mean square deviation (rmsd) of ~ 1.1 Å for 185–186 α carbon backbone atoms aligned). This low rmsd provides support that the toxin HigB does not induce large conformational rearrangements of HigA upon binding in contrast to other systems as mentioned above. However, one noticeable change is seen at the HigA dimer interface (Fig. 2C). Aligning a single protomer of the HigA dimer reveals a movement of HTH α -helices 1, 2, and 3 backbone residues of ~ 4.0 Å and a shift outward of 5.1° in the absence of toxin HigB (Fig. 2C). This movement increases the distance between each HTH motif by ~ 1.5 Å (to 29.4 Å from 27.9 Å as measured from Arg40 in each protomer) as compared to the HigA dimer in the HigBA complex (Schureck et al. 2014). If the spacing between $\alpha 3$ of the two HigA protomers is important for recognition of the *hig* operator, the remodeling of the HigA dimeric interface induced by HigB binding could modulate the strength of HigB binding to *hig*.

Structure of HigA bound to *higO2*.

To understand how HigA recognizes its operator at the molecular level, we solved the X-ray crystal structure of HigA bound to the *higO2* DNA operator to 2.9 Å (Fig. 3; Table S1). The HigA-DNA complex crystallizes in the space group P6₅ with three HigA dimers and three 21 nucleotide, double-stranded DNA in the asymmetric unit. The final HigA model was built for residues 4–92 and 4–91 (out of 104 total residues) in dimer A, 5–92 and 5–95 for dimer B, and 6–96 and 7–92 for dimer C. The three HigA dimers in the asymmetric unit are similar with rmsd values ranging 0.424 – 0.537 Å. A DALI search reveals that HigA-DNA is similar to the *Shewanella oneidensis* HipA-HipB-DNA toxin-antitoxin complex (PDB code 4PU4), *Pseudomonas aeruginosa* transcriptional repressor RsaL-DNA complex (PDB code 5J2Y), and *Escherichia coli* HipB antitoxin-DNA complex (PDB code 4YG1) with Z-scores of 6.2,

5.8, and 5.3, and r.m.s.d. values of 5.5, 2.1, and 2.9 Å, respectively (using 66, 55 and 59 aligned Ca atoms, respectively) (Holm and Rosenstrom 2010).

Each HigA dimer recognizes a single inverted repeat of the operator with no apparent crosstalk between HigA dimers (Fig. 3A). Sequence specific interactions are mediated by $\alpha 3$ recognition of the nucleobases in the major groove while sequence-independent interactions with the phosphate backbone on the opposite strand are mediated by the $\alpha 1$ - $\alpha 2$, $\alpha 2$ - $\alpha 3$ and $\alpha 3$ - $\alpha 4$ loops. As is often the case with HTH motifs (Shimon and Harrison 1993), three residues (Thr34, Thr36 and Arg40) are displayed on the surface of the $\alpha 3$ recognition helix facing the major groove of the inverted operator repeats (Fig. 3B). The hydroxyl groups of Thr34 and Thr37, and the backbone amine of Thr34, interact with the G_{+7} phosphate while the side chain methyl groups of Ala36 and Thr34 form van der Waals interactions with the nucleobase C5 methyl of T_{+6} (Fig. 3C). HigA also makes hydrophobic interactions in recognition of the operator via the side chain methyl group of Thr46 with the C5 methyl of T_{+8} . Sequence-specific interactions include hydrogen bonds between the hydroxyl groups of Ser23 and Ser39 with the G_{+12} and T_{+10} phosphate oxygens, respectively, and an ionic interaction between the Lys45 amino and the T_{+9} phosphate oxygen. Non-sequence specific interactions between HigA and its operator are between the backbone amines of both Gly24 and Arg25 and the phosphate oxygens of A_{+11} .

HigA $\alpha 3$ residue Arg40 specifically recognizes the DNA major groove. The Arg40 side chain guanidino moiety makes bifurcated hydrogen bonding interactions with the Hoogsteen face of G_{+7} (via the O6 and N7 atoms) (Fig. 3B). Additionally, the guanidino moiety stabilizes interactions with the C5 methyl group of T_{+8} via cation-pi interactions. The interaction between Arg40 and the $T_{+8}G_{+7}$ dinucleotide is similar to an evolutionary conserved mode of recognition of TG and methylated CG dinucleotides by prokaryotic and eukaryotic transcription factors termed YpG interactions (where Y indicates a pyrimidine) (Lamoureux et al. 2004; Liu et al. 2013). Together, these interactions likely facilitate HigA specific recognition of *higO2*.

To identify how HigA binding might alter *higO2*, we analyzed the backbone and nucleobase geometry of *higO2* DNA using the program Curves+ (Blanchet et al. 2011). The most prominent finding of this analysis was that there are local deformations of the major and minor grooves as compared to B-form DNA. In the structure of HigA bound to *higO2*, the major groove was narrowed at the site where the HTH inserts (~ 9.9 – 10 Å) and widens (~ 11.8 Å) between both HTH motifs on the opposite side of the DNA (Fig. S1) (the major groove of B-form DNA is 11.4 Å). Likewise, the minor groove expands (~ 7.4 – 7.7 Å) on the opposite side of where the HTH motifs contact DNA and contracts in the center of *higO2* between the HigA monomers (~ 6.9 Å). These backbone deformations from B-form DNA may be required to facilitate productive HigA-DNA interactions (Fig. S1).

Arginine 40 governs *hig* recognition and transcriptional repression by HigA.

To investigate the importance of Arg40 in operator recognition, we constructed a HigA variant with an Arg40 to Ala substitution and analyzed its function both *in vivo* and *in vitro*. To confirm that Arg40 is important for the transcriptional repression function of HigA and not its toxin neutralization function, we performed the spot-dilution assay used described in

Fig. 1C to evaluate the ability of the point mutant to inhibit HigB toxicity. Normal cell growth was observed when HigB and the HigA R40A variants were co-expressed, indicating that HigA Arg40 was dispensable for its toxin neutralization function *in vivo* (Fig. 4A). To examine the importance of Arg40 in the ability of HigA to control *higB-higA* transcription, a pBAD33 plasmid with the HigA R40A variant was introduced into *E. coli* BW25113 bearing the *Phig-lacZ* transcriptional reporter plasmid. When the strain was grown to mid-exponential phase in minimal medium with 0.2% arabinose, it produced nearly the same amount of β -gal activity as the strain with pBAD33 without *higA* (Fig. 4B). This result demonstrates that Arg40 is important for HigA to repress transcription from the *hig* promoter. We next determined that HigA R40A is unable to bind to its DNA operator *in vitro*, even up to a concentration of 1 μ M HigA R40A protein (Fig. 4C). Further, we confirmed that HigA R40A retained its ability to form a dimer (molecular weight of ~30 kDa), an oligomeric state known to be required for DNA binding *in vitro* (Schureck et al. 2014) (Fig. 4D). Lastly, we mutated both guanosines in each inverted repeat to adenosines (G_{+7} as shown in Fig. 4B) and observed no wild-type HigA binding (again to a concentration of 1 mM) (Fig. 4E). These data demonstrate that HigA Arg40 is important for operator recognition and interacts specifically with nucleotide G_{+7} but is not critical for HigA dimerization or HigB neutralization.

Comparison of HigBA, HigA and HigA-*higO2* structures.

Although the HigB toxin is not required for the formation of the HigA dimer (Schureck et al. 2014), binding of HigB does influence the overall architecture of HigA as evidenced by superimposition (Fig. 5A). The distance between the HigA HTH motifs located in each protomer when bound to HigB is 27.2 Å (as measured by the distance between Arg40 located in the middle of each operator recognition helix α 3 of each promoter). HigA binding to *higO2* increases the distance between the HTH motifs to by ~4 Å to 31.0 Å and moves a HigA promoter 12° relative to the other promoter. This movement is necessary to expand the distance between the two recognition helices of the HigA dimer to bind to the two inverted repeat sequences and two major grooves of the operator. In the presence of HigB, the distance between the HTH motifs decreases to a distance that would cause a steric clash between HigA helix α 3 and *higO2* (Fig. 5A).

These structural comparisons also suggest other changes to HigA that may occur upon HigB binding (Fig. 5B). For example, in the presence of the toxin HigB but the absence of *higO2*, the N-terminal loop of HigA packs against HigB and forms a hydrogen bonding and salt bridge network between HigA residues Arg2 and Gln3 with Glu80 and Arg77 of HigA α 5, respectively (Fig. 5B, top). In the HigA dimer structure solved in this study, these interactions between HigA loop 1 and α 5 are weakened by rotation of α 5 residues that ablate and remodel these interactions (Fig. 5B, bottom). This disruption between Arg2 and Glu80 is also seen in the HigA-*higO2* operator structure. Considering that the HigA dimerization occurs at the α 5- α 5 interface and remodeling of the HigA protomers relative to the other in the absence of HigB appears to be mediated by the α 5- α 5 interface (Fig. 2A, 2C), the consequence of disrupting interactions between HigA loop 1 and α 5 may contribute to the increase in distance between HigA HTH recognition helices (Fig. 5A). These

structural comparisons suggest that HigB may help to rigidify HigA's conformational freedom of rotation.

The HigBA complex binds two-fold less tight than HigA to *higO1* or *higO2*.

Previously, we and others have found that the HigBA complex binds DNA (Tian et al. 2001; Schureck et al. 2014). However, it is unclear how the conformational changes observed in HigA alone versus in complex with HigB will affect operator binding. Therefore, we next performed electromobility shift assays (EMSAs) to assess the ability of purified HigA or HigBA to bind to a 61 base-pair DNA fragments that contained *higO1* with *higO2* sequence scrambled or *higO2* with *higO1* sequence scrambled (Fig. 6 and Fig. S2). HigA binds to each of operator with approximately the same affinity (K_d values of 140 ± 0.03 and 125 ± 0.03 nM for *higO1* with *higO2*, respectively). Interestingly, HigBA binds to each operator with a ~2-fold lower affinity (K_d values of 364 ± 0.10 and 243 ± 0.04 nM for *higO1* with *higO2*, respectively) (Fig. 6B and Fig. S2).

DISCUSSION

Much of what is known about the transcriptional regulatory mechanisms that establish and maintain appropriate levels of toxin-antitoxin complexes has been derived from the careful examination of a small set of model systems (reviewed in (Loris and Garcia-Pino 2014; Page and Peti 2016)). Studies of these model systems have led to significant advances in our understanding of how toxin-antitoxins are regulated but it is unclear whether this understanding can be broadly applied across diverse classes of toxin-antitoxins. One potential reason for the possibility of different repressor mechanisms is the rich diversity in the structure of antitoxins. Four predominant motifs are exploited by antitoxins for DNA binding: the RHH, Phd/YefM, SpoVT/AbrB or HTH motifs. There are only three known HTH-containing antitoxins and even among this group, there are clear differences in how they regulate transcriptional repression. For example, both antitoxins HipB and MqsA cause substantial DNA bending while we find in this study that HigA does not (Schumacher et al. 2009; Brown et al. 2013). Also, the direct and indirect readout of the operator sequences occurs by distinct mechanisms. We demonstrate that HigA recognizes its operator via a mechanism employed by both prokaryotic and eukaryotic transcription factors whereby the side chain of a conserved arginine residue makes both nucleobase-specific interactions with a guanosine and pi-cation stacking interactions with an adjacent thymine in recognition of a YpG dinucleotide (Lamoureux et al. 2004; Liu et al. 2013). In contrast, antitoxins HipB and MqsA do not recognize YpG dinucleotides. These data indicate that antitoxins containing HTH DNA-binding motifs do not necessarily use the same mechanism of transcriptional repression.

Previously it has been shown that regulation of transcription of toxin-antitoxin operons can be mediated by higher order toxin-antitoxin complexes, which are regulated by excess toxin functioning as a co-repressor (Afif et al. 2001; Overgaard et al. 2008; Garcia-Pino et al. 2010). For example, when CcdB, RelE or Doc toxins are present at levels below those of their cognate antitoxins, toxin binding to antitoxin-DNA operator sites increases the overall affinity and the level of repression at the toxin-antitoxin operon (Magnuson and Yarmolinsky

1998; Afif et al. 2001; Garcia-Pino et al. 2010). On a molecular level for the RelBE system which is the most similar to the HigBA system, this high affinity complex has been proposed to be a trimeric toxin-antitoxin complex (two antitoxins and one toxin molecule) when bound to its DNA operator (Overgaard et al. 2008; Boggild et al. 2012). At present, only a structure of the tetrameric RelBE complex has been observed in the absence of DNA (Boggild et al. 2012). As toxin levels increase to those similar to the antitoxin, the additional toxin disrupts the antitoxin-operator complexes and transcriptional repression is relieved (Overgaard et al. 2008). Additionally, in these systems, the antitoxin C terminus is disordered in the absence of its cognate toxin and gains structure upon toxin binding which also leads to an increase binding affinity for its DNA operator. These conditional co- and anti-repressor functions of toxins and their influence on antitoxin structure are the hallmarks of the current models describing toxin-antitoxin regulation.

Structural comparisons of *apo* HigA, HigA-*higO2* complex and HigBA provide insights into how transcriptional repression could be mediated in this system. First, we find that the antitoxin HigA does not undergo a disorder-to-order transition at its C terminus in contrast to well-studied toxin-antitoxin systems (Magnuson and Yarmolinsky 1998; Afif et al. 2001; Overgaard et al. 2008; Garcia-Pino et al. 2010). Instead, we determine that the C terminus of HigA is required for its dimerization and this oligomeric state is, in turn, is necessary for DNA operator binding, despite each HigA monomer containing a single DNA operator. Toxin HigB binding does not order HigA providing further support that this system is not regulated by a disorder-to-order mechanism. Lastly, the HigBA complex, that we presume from our previous two crystal structures is a tetrameric complex (two HigBs and two HigAs) in the absence of DNA (Schureck et al. 2014), binds with a ~two-fold lower affinity than antitoxin HigA alone. These data demonstrate that toxin HigB does not function as a co-repressor in contrast to a number of other systems. Interestingly, in the case of the antitoxin MqsA, its cognate toxin MqsR also does not function as a co-repressor and shares a binding surface on MqsA with its operator DNA, effectively functioning as a competitor (Brown et al. 2013). One formal possibility is that the oligomeric state of HigBA changes in the context of binding the *hig* promoter, however, further detailed biophysical or structural insights are needed to unravel these molecular details.

These data together suggest a possible explanation for how toxin HigB may modulate the ability of the HigA antitoxin to repress transcription of the *higBA* genes. When HigB is present at levels below those of HigA, HigA binds tightly to its operator sites within the *hig* promoter and represses expression of *higBA* genes. When HigB reaches levels similar to those of HigA, the binding of two HigB monomers to the HigA dimer may restrict the complex to a conformation that is less favorable for operator binding than HigA alone. Indeed, structural superimpositions demonstrate that there are clashes of HigA's DNA-binding motifs in the HigBA complex with *higO2*. Perhaps a single toxin HigB could bind to the HigA dimer which may not result in clashes with *higO2*, but at this time, there is no direct evidence that a trimeric HigBA exists. This possible model for how HigB could modulate the ability of HigA to repress gene expression is attractive in that it serves the same operating principles as those invoked to understand the well-studied toxin-antitoxins but does so through a distinct set of molecular mechanisms.

EXPERIMENTAL PROCEDURES

General methods.

The strains, plasmids, and oligonucleotide primers used in this study are listed in Tables S2, S3, and S4, respectively. Strains were grown in lysogeny broth (LB; 1% tryptone, 0.5% yeast extract, 1% sodium chloride) and M9 minimal medium (48 mM sodium phosphate dibasic, 22 mM potassium phosphate monobasic, 8.6 mM sodium chloride, 19 mM ammonium chloride, 2.0 mM magnesium sulfate, 0.1 mM calcium chloride) with 0.4% maltose. When necessary, strains were grown in media supplemented with 100 $\mu\text{g ml}^{-1}$ ampicillin, 20 $\mu\text{g ml}^{-1}$ chloramphenicol, or 30 $\mu\text{g ml}^{-1}$ kanamycin.

Plasmid construction.

To build a replicating plasmid with a *lacZ* transcriptional reporter for the Rts1 *hig* promoter, oligonucleotides oJM835 and oJM836 were annealed and then ligated to pQF50 that had been cut with PstI and HindIII to make pQF50 *Phig-lacZ* (pJM359) (Table S3). The pQF50 plasmid contains a multiple cloning site immediately upstream of a *lacZ* reporter gene with the strong ribosome-binding site from the *E. coli lpp* gene. To build a similar replicating plasmid with the *higBA* and *lacZ* genes under the control of the *hig* promoter, a DNA fragment containing the *hig* promoter, *higB*, and *higA* was chemically synthesized (IDT). The fragment was cut with PstI and HindIII and ligated to pQF50 cut with the same restriction enzymes to make pQF50-*Phig-higBA-lacZ*.

To construct a replicating plasmid with *higB* under the control of an inducible promoter, the *higB* sequence was amplified by PCR from pQF50-Rts1 *Phig-higBA-lacZ* with oligonucleotide primers oJM821 and oRJD2. The *higB* PCR product, as well as the pBAD33 plasmid (Guzman et al. 1995), were cut with PstI and HindIII, and then ligated to make pBAD33-*higB* (pJM346). A series of plasmids were also built containing both *higB* and *higA* under the control of the arabinose-inducible promoter in pBAD33. The *higB-higA* sequence was amplified by PCR from pQF50-Rts1 *Phig-higBA-lacZ* with oligonucleotide primers oJM821 and oJM837, cut with PstI and HindIII, and then ligated to pBAD33 cut with the same restriction enzymes. To build a derivative of this plasmid with the C-terminally truncated HigA, *higA 84-104* was amplified from pQF50-Rts1 *Phig-higBA-lacZ* with oJM821 and oJM862, cut with PstI and HindIII, and then ligated to pBAD33. To make a derivative with the HigA R40A mutant, pBAD33-*higB-higA* was subjected to site-directed mutagenesis (according to the Stratagene QuikChange protocol) with oJM870 and oJM871. All pBAD33 plasmids were confirmed by sequencing (Genewiz).

To build a transcriptional reporter plasmid with the *higA* and *lacZ* genes under the control of the *hig* promoter, oligonucleotides oJM863 and oJM864 were annealed and then ligated to pQF50 that had been cut with SphI and BamHI to make pQF50 *Phig-lacZ* (pJM379). The *higA* sequence was amplified by PCR from pQF50-Rts1 *Phig-higBA-lacZ* with oligonucleotide primers oJM865 and oJM837. The PCR product was cut with BamHI and HindIII, and then ligated to pJM379 cut with the same restriction enzymes to make pQF50 *Phig-higA-lacZ* (pJM384). The C-terminally truncated *higA*, *higA 84-104*, was also

amplified with oligonucleotide primers oJM865 and oJM837, cut with BamHI and HindIII, and then ligated to pJM379 to make pQF50 *Phig-higA 84–104-lacZ* (pJM385).

To construct a plasmid with *higA* under the control of the arabinose inducible promoter, the *higA* sequence was amplified by PCR from pQF50-Rts1 *Phig-higBA-lacZ* with oligonucleotide primers oJM823 and oJM837. The PCR product was cut with PstI and HindIII, and then ligated with pBAD33 cut with the same restriction enzymes. To build a version of this plasmid containing the C-terminally truncated *higA*, *higA 84–104* was amplified from pQF50-Rts1 *Phig-higBA-lacZ* with oJM823 and oJM862, cut with PstI and HindIII, and then ligated with pBAD33. To make a derivative with the *higAR40A* mutant, pBAD33-*higA* was subjected to site-directed mutagenesis with oJM870 and oJM871.

The expression plasmid used in this study, pET28a-his6-Rts1 *higA*, was a generous gift from the Woychik laboratory (Hurley and Woychik 2009). To make a derivative of this expression plasmid with the *HigA R40A* variant, pET28a-his6-Rts1 *higA* was subjected to site-directed mutagenesis with oJM870 and oJM871. The plasmids were confirmed by sequencing (Genewiz) using oJM437 and oJM438.

Spot dilution assays.

Strains were grown in 3 mL LB supplemented with chloramphenicol at 37°C with rolling to an OD₆₀₀ of 0.5–1.0. The cultures were then serially diluted 10-fold in LB, 5 µl of each dilution (10⁻¹ to 10⁻⁶ dilutions) was spotted on LB agar with chloramphenicol or LB agar with chloramphenicol and 0.2% arabinose, and cells were grown at 37°C overnight.

β-galactosidase assays.

Strains were grown in 3 mL medium (LB or M9 maltose) at 37°C with rolling until cell density reached until an OD₆₀₀ of 0.5. Cultures were diluted 100-fold into 20 ml medium with or without 0.2% arabinose and grown at 37°C with rolling to an OD₆₀₀ of ~0.5 (mid-exponential growth phase). 1 mL of each culture was centrifuged at 10,000 *x g* in a microcentrifuge tube for 1 min and cell pellets were stored at –20°C. Cell pellets were thawed on ice and resuspended in 500 µl cold buffer (60 mM sodium phosphate dibasic, 40 mM sodium phosphate monobasic, 10 mM potassium chloride, 1 mM magnesium sulfate, pH 7.0 with 50 mM β-mercaptoethanol). 10–200 µl of each cell suspension was added to microcentrifuge tubes containing 800–990 µl buffer (to a final combined volume of 1 mL, 100 µl chloroform, and 50 µL 0.1% SDS. Reactions were vortexed and incubated at 30°C for 10 min. 200 µl 4 mg ml⁻¹ ortho-nitrophenyl-β-galactosidase (in 0.1 M phosphate buffer, 60 mM sodium phosphate dibasic, 40 mM sodium phosphate monobasic, pH 7.0) was added to each sample. Reactions were vortexed briefly and incubated at 30°C for 10–30 min. Each reaction was terminated by the addition of 400 µL of 1 M sodium carbonate, vortexed and centrifuged to remove cell debris. 1 mL of each reaction supernatant was transferred to disposable cuvettes. Absorbance of each reaction was measured at 420 nm. β-galactosidase activity (in Miller units) was calculated as follows: (1000 × A₄₂₀)/(reaction time in minutes × cell suspension volume in mL × OD₆₀₀).

HigA and HigA variant expression and purification.

To overexpress wild-type Rts1 HigA or the HigA R40A variant, the expression strain *E. coli* BL21(DE3) was transformed with pET28a-his6-*higA* or pET28a-his6-*higAR40A* (pJM382) to make strains BL21(DE3) pET28a-his6-*higA* (ECJM901) and BL21(DE3) pET28a-his6-*higA R40A* (ECJM902), respectively. These expression strains were grown in 20 ml LB supplemented with kanamycin at 37°C with shaking. When the cultures reached mid-exponential phase (optical density (OD) at 600 nm of approximately 0.5), they were transferred to a 2.8 L baffled Fernbach flasks containing 1 L LB with kanamycin and incubated at 37°C with shaking. Once the cultures reached an OD₆₀₀ of 0.6–0.7, they were cooled at 4°C for 15 min. Then 50 µl 1 M isopropyl-1-thio-β-D-galactopyranoside (IPTG) was added to the 1 L cultures to give a final concentration of 50 µM, and the cultures were incubated at 18°C with shaking overnight (~18 hrs). The cultures were then centrifuged, the supernatants were removed, and the cell pellets were stored at –80°C.

To purify the wild-type and protein variants, the frozen cell pellets were thawed and resuspended in 25 ml HisTrap buffer A (50 mM Tris, 250 mM KCl, 5 mM MgCl₂, 5 mM imidazole, 5 mM β-mercaptoethanol, 10% glycerol, pH 7.4) with ProBlock Gold protease inhibitor (GoldBio) and 50 µl 10 mg/ml DNase I. The cells were lysed with French press at 15,000 psi. The resulting cell lysates were centrifuged at 10,000 x *g* at 4°C for 20 min. Cleared lysates were filtered and loaded onto 5 ml HisTrap HP column in an ÄKTApurifier chromatography system (GE Healthcare). His6-tagged proteins were eluted from the column with an increasing linear gradient of HisTrap buffer B (50 mM Tris, 250 mM KCl, 5 mM MgCl₂, 500 mM imidazole, 5 mM β-mercaptoethanol, 10% glycerol, pH 7.4). To remove the hexahistidine tag, HisTrap elution fractions were pooled and incubated with thrombin (1 unit per mg of protein) at room temperature for 2 hrs and then at 4°C overnight. The thrombin proteolysis reactions were subjected to size exclusion chromatography on a HiLoad 16/60 Superdex 200 column and buffer exchanged into storage buffer (40 mM Tris-HCl, pH 7.5, 250 mM KCl, 5 mM MgCl₂, and 5 mM β-mercaptoethanol). To remove any remaining thrombin or His-tagged HigA protein, the gel filtration fractions were pooled and loaded onto 1 ml HiTrap Benzamidin FF and 1 mL HisTrap FF columns arranged in tandem. Finally, HigA was dialyzed back into storage, concentrated and stored in aliquots at –80°C. The HigA protein lacking any tags is 11.5 kDa.

HigA crystallization, data collection, and structure determination.

HigA crystals (10 mg ml⁻¹) were grown by sitting drop vapor diffusion in 0.2 M NaSCN and 20% w/v polyethylene glycol (PEG) 3350 at 20°C. Crystals were cryoprotected by gradually increasing the ethylene glycol concentration to 30% w/v while decreasing the PEG 3,350 concentration to 10% w/v followed by freezing in liquid nitrogen. Three hundred and sixty degrees of diffraction data were collected at the Northeastern Collaborative Access Team (NE-CAT) beamline 24-IDC at the Advanced Photon Source (APS) (Chicago, IL, USA). The x-ray diffraction data were indexed, integrated and scaled in XDS (Kabsch 2010). The structure was solved by molecular replacement using a HigA monomer from the HigB-HigA complex (PDB code 4MCT) as a search model in PHENIX AutoMR to 1.9 Å (Adams et al. 2010). Two HigA proteins per asymmetric unit were identified and form a dimer within the asymmetric unit. The model was built in Coot (Emsley et al. 2010) for

residues 3–94 and 6–99 followed by refinement of xyz coordinates, occupancies and B-factors in PHENIX (Adams et al. 2010) to a final $R_{\text{work}}/R_{\text{free}}$ of 17.5/22.2%.

Analytical ultracentrifugation studies of HigA.

Purified HigA was dialyzed against 20 mM Tris, 100 mM NaCl, 10 mM MgCl_2 , pH 7.5. Sedimentation velocity experiments were performed on a 0.11 mg/mL sample (0.4 mL) at $182,000 \times g$ (50,000 rpm) at 20°C in a Beckman Coulter ProteomeLab XLI analytical ultracentrifuge using standard procedures (Zhao et al. 2013). Absorbance scans were taken at 280 nm in continuous mode using a radial spacing of 0.003 cm at approximately 3.6 min intervals in an An-60 rotor equipped with 12 mm path length double sector cells and sapphire windows. Absorbance values were fit to the Lamm equation along with the meniscus position, baseline and time-invariant noise using the continuous $c(s)$ distribution model of SEDFIT, version 15.01c (<http://analyticalultracentrifugation.com>) integrating between 0 and 10 S at 0.1 S increments (Schuck 2000; Dam and Schuck 2004). Fitting was done using maximum entropy regularization with a confidence interval of 0.68. Both the simplex and Marquardt-Levenberg nonlinear least squares fitting algorithms were tested and produced equivalent results. Buffer density, viscosity and the partial specific volume of HigA (0.730 mL g^{-1}) were estimated using SEDNTERP (<http://sednterp.unh.edu>) (Cole et al. 2008). The sedimentation coefficient was corrected to $s_{20,w}$ using the buffer density and viscosity. The molecular weight of HigA was obtained from the $c(s)$ peak by deconvolution of the contribution of diffusion to the observed signal as described (Schuck 2000; Dam and Schuck 2004). AUC results were plotted using GUSI version 1.2.1 (Schuck P 2016).

HigA-DNA operator complex crystallization, data collection, and structure determination.

The *hig* operator 2 DNA was formed by incubating two 21 nt (pHigCryst3 and pHigCryst4), single-stranded DNA at 95°C for 2 mins and then cooled to room temperature for two hrs in DNA buffer (100 mM NaCl, 1 mM EDTA and 10 mM Tris, pH 8.0). HigA (3.2 mg mL^{-1}) was complexed with 1.6 mg mL^{-1} of the *hig*O2 DNA in 1X binding buffer (20 mM Tris, pH 8, 100 mM NaCl, 10 mM MgCl_2) to form a complex consisting of 1 HigA dimer per 1 duplex DNA molar ratio. Crystals were grown by sitting drop vapor diffusion in 0.2 M CaCl_2 and 10–25% w/v PEG 3,350 at 20°C producing rod-shaped crystals after two days. Crystals were cryoprotected by three serially increases of ethylene glycol to final concentration of 30% w/v followed by freezing in liquid nitrogen. The HigA-DNA crystals are of the $P6_5$ space group and diffracted anisotropically. A total of 120° of diffraction data was collected on the SER-CAT 22ID beamline. The data were indexed, integrated and scaled to 2.9 \AA in XDS (Kabsch 2010). Structure determination was performed by molecular replacement using the structure of HigA in isolation as a search model in PHENIX AutoMR (Adams et al. 2010). Three copies of a HigA dimer bound to double-stranded DNA are found per asymmetric unit. Manual modification of the model was performed in Coot (Emsley et al. 2010) followed by refinement of XYZ coordinates with secondary structure restraints and B-factors in PHENIX. The final model has an $R_{\text{work}}/R_{\text{free}}$ of 22.5/26.0%. All figures were created in PyMOL (Schrodinger 2010). Alignments between HigBA, HigA, and HigA-DNA were constructed using either the secondary structure matching or least-squares fit functions in Coot (Emsley et al. 2010).

Electromobility shift assay (EMSA).

To construct the double-stranded DNA (dsDNA) for the EMSA, pairs of complementary single-stranded oligonucleotides were diluted to 2 μ M each in 10 mM Tris, 1 mM EDTA, 100 mM NaCl, pH 8.0. The 61-nt oligonucleotide mixtures of the *hig* promoter fragment were incubated at 95°C for 2 min and then cooled at room temperature for 2 hr. The wild-type operator was generated from pHigA_F and pHigA_R, scrambled operator 1 with wild-type operator 2 from pHigA_F_Scra1 and pHigA_R_Scra1 and wild-type operator 1 and scrambled operator 2 from pHigA_F_Scra2 and pHigA_R_Scra2. For the EMSA, the dsDNA oligos were diluted to 150 nM in EMSA binding buffer (100 mM NaCl, 10 mM MgCl₂, 5% glycerol, 0.01 mg/ml BSA). Purified wild-type HigA and HigA R40A proteins were diluted to 10 μ M in EMSA binding buffer and serially diluted to give a series of final protein concentrations ranging from 62.5 nM to 1.0 μ M in the EMSAs. HigBA was purified as previously described (Schureck et al. 2014) and diluted to 8 μ M in EMSA binding buffer and serially diluted to give a series of final protein concentrations ranging from 25 nM to 600 nM in the EMSAs. The binding reactions were incubated on ice for 20 min and 5 μ L of each reaction was loaded onto an 8% native, polyacrylamide-0.5X TBE-glycerol gels (50 mM Tris, 50 mM boric acid, 5 mM EDTA, 10% glycerol) and subjected to electrophoresis at 100 volts at 4°C. To visualize the DNA and DNA-protein complexes, the gels were stained with SYBR green nucleic acid gel stain (ThermoFisher Scientific) in 0.5X TBE glycerol for 30 mins with gentle agitation, and then the fluorescence was imaged with a Typhoon Trio phosphoimager (GE Healthcare; 488 nm excitation and 526 nm emission). Assays were performed in duplicate with representative gels shown. Band intensities for both free and bound *hig* DNA were quantified with ImageQuant 1D gel analysis using the rolling ball background subtraction. For HigA or HigBA bound to either *hig*O1 or *hig*O2, the *hig* DNA were fit using a one site specific binding equation in GraphPad

$$(\text{Fraction bound} = \frac{\text{bound}}{\text{free} + \text{bound}}).$$

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

This work was supported by in part by a National Science Foundation CAREER award MCB 0953714 (CMD), a National Institutes of Health (NIH) Biochemistry, Cellular and Developmental Biology Graduate Training Grant (5T32GM8367), and a NIH National Research Service Award Fellowship GM108351 (MAS). CMD is a Burroughs Wellcome Fund Investigator in the Pathogenesis of Infectious Disease. We thank F. M. Murphy IV and staff members of the NE-CAT beamlines for assistance during data collection, Dr. G. Conn for critical reading of the manuscript, and Dunham lab member S. Miles for technical assistance. This work is based upon research conducted at the NE-CAT beamlines, which are funded by the NIGMS from the NIH (P41 GM103403), and at the SER-CAT beamline. The Pilatus 6M detector on 24-ID-C beam line is funded by a NIH-ORIP HEI grant (S10 RR029205). This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357.

REFERENCES

- Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N et al. 2010 PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta crystallographica* 66: 213–221.
- Afif H, Allali N, Couturier M, Van Melderen L. 2001 The ratio between CcdA and CcdB modulates the transcriptional repression of the ccd poison-antidote system. *Mol Microbiol* 41: 73–82. [PubMed: 11454201]
- Blanchet C, Pasi M, Zakrzewska K, Lavery R. 2011 CURVES+ web server for analyzing and visualizing the helical, backbone and groove parameters of nucleic acid structures. *Nucleic Acids Res* 39: W68–73. [PubMed: 21558323]
- Boggild A, Sofos N, Andersen KR, Feddersen A, Easter AD, Passmore LA, Brodersen DE. 2012 The crystal structure of the intact *E. coli* RelBE toxin-antitoxin complex provides the structural basis for conditional cooperativity. *Structure* 20: 1641–1648. [PubMed: 22981948]
- Brown BL, Grigoriu S, Kim Y, Arruda JM, Davenport A, Wood TK et al. 2009 Three dimensional structure of the MqsR:MqsA complex: a novel TA pair comprised of a toxin homologous to RelE and an antitoxin with unique properties. *PLoS Pathog* 5: e1000706. [PubMed: 20041169]
- Brown BL, Lord DM, Grigoriu S, Peti W, Page R. 2013 The *Escherichia coli* toxin MqsR destabilizes the transcriptional repression complex formed between the antitoxin MqsA and the mqsRA operon promoter. *J Biol Chem* 288: 1286–1294. [PubMed: 23172222]
- Christensen SK, Maenhaut-Michel G, Mine N, Gottesman S, Gerdes K, Van Melderen L. 2004 Overproduction of the Lon protease triggers inhibition of translation in *Escherichia coli*: involvement of the yefM-yoeB toxin-antitoxin system. *Mol Microbiol* 51: 1705–1717. [PubMed: 15009896]
- Christensen-Dalsgaard M, Jorgensen MG, Gerdes K. 2010 Three new RelE-homologous mRNA interferases of *Escherichia coli* differentially induced by environmental stresses. *Mol Microbiol* 75: 333–348. [PubMed: 19943910]
- Cole JL, Lary JW, T PM, Laue TM. 2008 Analytical ultracentrifugation: sedimentation velocity and sedimentation equilibrium. *Methods Cell Biol* 84: 143–179. [PubMed: 17964931]
- Dam J, Schuck P. 2004 Calculating sedimentation coefficient distributions by direct modeling of sedimentation velocity concentration profiles. *Methods Enzymol* 384: 185–212. [PubMed: 15081688]
- De Jonge N, Garcia-Pino A, Buts L, Haesaerts S, Charlier D, Zangger K et al. 2009 Rejuvenation of CcdB-poisoned gyrase by an intrinsically disordered protein domain. *Mol Cell* 35: 154–163. [PubMed: 19647513]
- Dienemann C, Boggild A, Winther KS, Gerdes K, Brodersen DE. 2011 Crystal structure of the VapBC toxin-antitoxin complex from *Shigella flexneri* reveals a hetero-octameric DNA-binding assembly. *Journal of molecular biology* 414: 713–722. [PubMed: 22037005]
- Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010 Features and development of Coot. *Acta crystallographica* 66: 486–501. [PubMed: 20383002]
- Garcia-Pino A, Balasubramanian S, Wyns L, Gazit E, De Greve H, Magnuson RD et al. 2010 Allosteric and intrinsic disorder mediate transcription regulation by conditional cooperativity. *Cell* 142: 101–111. [PubMed: 20603017]
- Garcia-Pino A, Christensen-Dalsgaard M, Wyns L, Yarmolinsky M, Magnuson RD, Gerdes K, Loris R. 2008 Doc of prophage P1 is inhibited by its antitoxin partner Phd through fold complementation. *J Biol Chem* 283: 30821–30827. [PubMed: 18757857]
- Gerdes K, Christensen SK, Lobner-Olesen A. 2005 Prokaryotic toxin-antitoxin stress response loci. *Nat Rev Microbiol* 3: 371–382. [PubMed: 15864262]
- Gonzalez Barrios AF, Zuo R, Hashimoto Y, Yang L, Bentley WE, Wood TK. 2006 Autoinducer 2 controls biofilm formation in *Escherichia coli* through a novel motility quorum-sensing regulator (MqsR, B3022). *J Bacteriol* 188: 305–316. [PubMed: 16352847]
- Guzman LM, Belin D, Carson MJ, Beckwith J. 1995 Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. *J Bacteriol* 177: 4121–4130. [PubMed: 7608087]

- Hadzi S, Garcia-Pino A, Haesaerts S, Jurenas D, Gerdes K, Lah J, Loris R. 2017 Ribosome-dependent *Vibrio cholerae* mRNAse HigB2 is regulated by a beta-strand sliding mechanism. *Nucleic Acids Res* 45: 4972–4983. [PubMed: 28334932]
- Harrison JJ, Wade WD, Akierman S, Vacchi-Suzzi C, Stremick CA, Turner RJ, Ceri H. 2009 The chromosomal toxin gene *yafQ* is a determinant of multidrug tolerance for *Escherichia coli* growing in a biofilm. *Antimicrob Agents Chemother* 53: 2253–2258. [PubMed: 19307375]
- Holm L, Rosenstrom P. 2010 Dali server: conservation mapping in 3D. *Nucleic Acids Res* 38: W545–549. [PubMed: 20457744]
- Hurley JM, Woychik NA. 2009 Bacterial toxin HigB associates with ribosomes and mediates translation-dependent mRNA cleavage at A-rich sites. *J Biol Chem* 284: 18605–18613. [PubMed: 19423702]
- Kabsch W 2010 Xds. *Acta crystallographica* 66: 125–132. [PubMed: 20124692]
- Kamada K, Hanaoka F. 2005 Conformational change in the catalytic site of the ribonuclease YoeB toxin by YefM antitoxin. *Mol Cell* 19: 497–509. [PubMed: 16109374]
- Kamada K, Hanaoka F, Burley SK. 2003 Crystal structure of the MazE/MazF complex: molecular bases of antidote-toxin recognition. *Mol Cell* 11: 875–884. [PubMed: 12718874]
- Kedzierska B, Lian LY, Hayes F. 2007 Toxin-antitoxin regulation: bimodal interaction of YefM-YoeB with paired DNA palindromes exerts transcriptional autorepression. *Nucleic Acids Res* 35: 325–339. [PubMed: 17170003]
- Kirkpatrick CL, Martins D, Redder P, Frandi A, Mignolet J, Chapalay JB et al. 2016 Growth control switch by a DNA-damage-inducible toxin-antitoxin system in *Caulobacter crescentus*. *Nat Microbiol* 1: 16008. [PubMed: 27572440]
- Lamoureux JS, Maynes JT, Glover JN. 2004 Recognition of 5'-YpG-3' sequences by coupled stacking/hydrogen bonding interactions with amino acid residues. *Journal of molecular biology* 335: 399–408. [PubMed: 14672650]
- Li GW, Burkhardt D, Gross C, Weissman JS. 2014 Quantifying absolute protein synthesis rates reveals principles underlying allocation of cellular resources. *Cell* 157: 624–635. [PubMed: 24766808]
- Li GY, Zhang Y, Inouye M, Ikura M. 2008 Structural mechanism of transcriptional autorepression of the *Escherichia coli* RelB/RelE antitoxin/toxin module. *Journal of molecular biology* 380: 107–119. [PubMed: 18501926]
- Liu Y, Zhang X, Blumenthal RM, Cheng X. 2013 A common mode of recognition for methylated CpG. *Trends Biochem Sci* 38: 177–183. [PubMed: 23352388]
- Loris R, Garcia-Pino A. 2014 Disorder- and dynamics-based regulatory mechanisms in toxin-antitoxin modules. *Chemical reviews* 114: 6933–6947. [PubMed: 24806488]
- Magnuson R, Yarmolinsky MB. 1998 Corepression of the P1 addiction operon by Phd and Doc. *J Bacteriol* 180: 6342–6351. [PubMed: 9829946]
- Moyed HS, Bertrand KP. 1983 *hipA*, a newly recognized gene of *Escherichia coli* K-12 that affects frequency of persistence after inhibition of murein synthesis. *J Bacteriol* 155: 768–775. [PubMed: 6348026]
- Overgaard M, Borch J, Jorgensen MG, Gerdes K. 2008 Messenger RNA interferase RelE controls relBE transcription by conditional cooperativity. *Mol Microbiol* 69: 841–857. [PubMed: 18532983]
- Page R, Peti W. 2016 Toxin-antitoxin systems in bacterial growth arrest and persistence. *Nat Chem Biol* 12: 208–214. [PubMed: 26991085]
- Ruangprasert A, Maehigashi T, Miles SJ, Giridharan N, Liu JX, Dunham CM. 2014 Mechanisms of Toxin Inhibition and Transcriptional Repression by *Escherichia coli* DinJ-YafQ. *J Biol Chem* 289: 20559–20569. [PubMed: 24898247]
- Schrodinger, LLC. 2010. The PyMOL Molecular Graphics System, Version 1.3r1.
- Schuck P 2000 Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. *Biophysical journal* 78: 1606–1619. [PubMed: 10692345]
- Schuck P ZH, Brautigam CA, Ghirlando R. . 2016 *Basic Principles of Analytical Ultracentrifugation*. CRC Press, Boca Raton.

- Schumacher MA, Piro KM, Xu W, Hansen S, Lewis K, Brennan RG. 2009 Molecular mechanisms of HipA-mediated multidrug tolerance and its neutralization by HipB. *Science* 323: 396–401. [PubMed: 19150849]
- Schureck MA, Dunkle JA, Maehigashi T, Miles SJ, Dunham CM. 2015 Defining the mRNA recognition signature of a bacterial toxin protein. *Proc Natl Acad Sci U S A* 112: 13862–13867. [PubMed: 26508639]
- Schureck MA, Maehigashi T, Miles SJ, Marquez J, Cho SE, Erdman R, Dunham CM. 2014 Structure of the *Proteus vulgaris* HigB-(HigA)₂-HigB toxin-antitoxin complex. *J Biol Chem* 289: 1060–1070. [PubMed: 24257752]
- Schureck MA, Maehigashi T, Miles SJ, Marquez J, Dunham CM. 2016a mRNA bound to the 30S subunit is a HigB toxin substrate. *RNA* 22: 1261–1270. [PubMed: 27307497]
- Schureck MA, Repack A, Miles SJ, Marquez J, Dunham CM. 2016b Mechanism of endonuclease cleavage by the HigB toxin. *Nucleic Acids Res* 44: 7944–7953. [PubMed: 27378776]
- Shimon LJ, Harrison SC. 1993 The phage 434 OR2/R1–69 complex at 2.5 Å resolution. *Journal of molecular biology* 232: 826–838. [PubMed: 8355273]
- Tian QB, Ohnishi M, Murata T, Nakayama K, Terawaki Y, Hayashi T. 2001 Specific protein-DNA and protein-protein interaction in the hig gene system, a plasmid-borne proteic killer gene system of plasmid Rts1. *Plasmid* 45: 63–74. [PubMed: 11322821]
- Tian QB, Ohnishi M, Tabuchi A, Terawaki Y. 1996 A new plasmid-encoded proteic killer gene system: cloning, sequencing, and analyzing hig locus of plasmid Rts1. *Biochem Biophys Res Commun* 220: 280–284. [PubMed: 8645296]
- Turnbull KJ, Gerdes K. 2017 HicA toxin of *Escherichia coli* derepresses hicAB transcription to selectively produce HicB antitoxin. *Mol Microbiol* 104: 781–792. [PubMed: 28266056]
- Van Melderen L, Bernard P, Couturier M. 1994 Lon-dependent proteolysis of CcdA is the key control for activation of CcdB in plasmid-free segregant bacteria. *Mol Microbiol* 11: 1151–1157. [PubMed: 8022284]
- Wang X, Kim Y, Hong SH, Ma Q, Brown BL, Pu M et al. 2011 Antitoxin MqsA helps mediate the bacterial general stress response. *Nat Chem Biol* 7: 359–366. [PubMed: 21516113]
- Watkins D, Hsiao C, Woods KK, Koudelka GB, Williams LD. 2008 P22 c2 repressor-operator complex: mechanisms of direct and indirect readout. *Biochemistry* 47: 2325–2338. [PubMed: 18237194]
- Zhao H, Lomash S, Glasser C, Mayer ML, Schuck P. 2013 Analysis of high affinity self-association by fluorescence optical sedimentation velocity analytical ultracentrifugation of labeled proteins: opportunities and limitations. *PLoS One* 8: e83439. [PubMed: 24358283]




Figure 1. HigA dimerization is dispensable for toxin inhibition but necessary for transcriptional repression.

A. Organization of the *hig* operon with the regions HigA recognizes shown in grey shading and the -35 and -10 promoter regions boxed. B. Spot dilution assay of *E. coli* BW25113 transformed with indicated plasmids, overexpressed and the indicated amounts were plated on LB and LB in the presence of 0.2% arabinose. C. β -gal assays of *E. coli* BW25113 transformed with indicated plasmids in LB medium. D. β -gal assays of *E. coli* BW25113 transformed with indicated plasmids in M9 maltose media and 0.2% arabinose.




Figure 2. HigA is an obligate dimer.

A. 1.9 Å X-ray crystal structure of HigA reveals the maintenance of the dimer interface in the absence of the HigB toxin. The DNA binding helix-turn-helix (HTH) motif and the dimer interface are indicated. B. Analytical ultracentrifugation of HigA produced a signal-average $s_{20,w}$ peak at 2.15 S corresponding to an estimated molecular weight of 25.9 kDa. C. Comparison of the HigA dimer (green) and HigA in the context of the HigBA complex (blue; PDB code 4MCT) reveals a 5° move away from the DNA binding surface involving $\alpha 1$, $\alpha 2$, and $\alpha 3$.




Figure 3. Structural basis of HigA-DNA operator recognition.

A. 2.9 Å X-ray crystal structure of HigA bound to *higO2*. One helix-turn-helix (HTH) motif of a HigA monomer is boxed. The *higO2* is shown with the blue arrows indicating the inverted repeats HigA recognizes and the specific nucleotides contacted are shown in bold. B. Zoomed in view of HigA $\alpha 2$ and $\alpha 3$ of the HTH motif that interact directly with nucleotides T₊₆, G₊₇ and T₊₈. HigA residue Arg40 hydrogen bonds to G₊₇. The phosphate of G₊₇ is contacted by Thr34 and Thr37 that may serve to stabilize the interaction between Arg40 and the nucleobase of G₊₇ (right panel). C. Schematic representation of interactions

between HigA residues with *higO2*. Van der waals interactions between Ala36 in both monomers is shaded grey.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 4. HigA Arg40 and G_{+7} are necessary for HigA recognition of *higO2*.

A. Spot dilution assay of *E. coli* BW25113 transformed with indicated plasmids, overexpressed with the indicated amounts were plated on LB and LB in the presence of 0.2% arabinose. B. β -gal assays of *E. coli* BW25113 transformed with indicated plasmids. C. Electrophoretic mobility shift assay of HigA R40A and *higO2*. D. Size exclusion chromatography analysis of HigA wild-type and the R40A variant. E. Electrophoretic mobility shift assay of the wild-type HigA and *higO2* containing a G_{+7} to A_{+7} mutation (along with a C_{+7} to U_{+7} to maintain Watson-Crick base-pairing).




Figure 5. Structural rearrangements of HigA during operator recognition.

A. Superposition of free HigA (this study), the HigB-HigA complex (PDB code 4MCT), and DNA operator-bound HigA (this study) using the second HigA monomer (grey) as an anchor point. The HigA dimer hinges $\sim 12^\circ$ away from the DNA surface upon DNA recognition as compared to HigA bound to HigB. In the context of both apo HigA and in the HigB-HigA complex, clashes between $\alpha 2$ and $\alpha 3$ with DNA would occur. Rearrangement of the one monomer of HigA is required to allow the HTH motif to fully engage DNA. B. The HigA N terminus packs against the toxin HigB and forms interactions with $\alpha 5$ that may restrict its conformation (top panel). In the absence of HigB, the interactions between loop 1 and $\alpha 5$ are disrupted (bottom panel).




Figure 6. HigA and HigBA recognition of *higO1* and *higO2*.

A. The band intensities from EMSAs as plotted as percent HigA bound versus HigA concentration for binding to *Phig* with scrambled *higO1* and of HigA and *Phig* with scrambled *higO2*. In each assay, the HigA concentration increases from 0–1000 nM (gel shown in Fig. S2). B. The band intensities from EMSAs as plotted as percent HigBA bound versus HigBA concentration for binding to *Phig* with scrambled *higO1* and of HigA and *Phig* with scrambled *higO2*. In each assay, the HigBA concentration increases from 0–600 nM (gel shown in Fig. S2). Curves represent the data from which binding affinities given in the main text were derived.